Recently we reported that Melan-A-specific CD8 T cells isolated from long-term surviving patients treated with DTIC before peptide-vaccination plus IFN-α possess higher anti-tumor reactivity and an enlarged T-cell repertoire, compared to cells isolated after vaccination alone, suggesting that chemoimmunotherapy may favor a protective anti-tumor specific immune response. Here, CD8A is linked to neoplasm.